Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal‑friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health. Summit’s leadership is committed to making a significant positive difference in the quality and potential duration of life for oncology patients facing difficult diagnoses. Summit has enacted the path to providing patient-, physician-, caregiver‑, and societal‑friendly therapies while creating opportunities for durable growth as a company by initiating several trials with its lead candidate, ivonescimab. Ivonescimab is known as SMT112 in Summit’s license territories: United States, Canada, Europe, Japan, Latin America (including Mexico, Central America, South America, and the Caribbean), the Middle East, and Africa; and as AK112 in Akeso's license territories, rest of world. Ivonescimab is known a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.

Ivonescimab displays cooperative binding with each of its intended targets, with higher affinity in the presence of both PD‑1 and VEGF. Ivonescimab was developed by Akeso, Inc. (HKEX Code: 9926.HK). It is currently being studied in several Phase 3 clinical trials in Summit’s license territories, in addition to multiple Phase 3 clinical trials in China led by Akeso. Summit has begun its clinical development of ivonescimab in non‑small cell lung cancer (NSCLC). Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

Summit intends to expand the opportunity and potential of ivonescimab into additional solid tumors in the future, based on promising data generated by its partners at Akeso in China. Globally, over 3,000 patients have been treated with ivonescimab across all clinical trials to date. Summit will continue to invest in its business and pipeline, driven by Team Summit’s unmatched capabilities, including speed and operational excellence, with the goal of bringing its mission into a reality.